STOCK TITAN

ProKidney Corp. - $PROK STOCK NEWS

Welcome to our dedicated page for ProKidney news (Ticker: $PROK), a resource for investors and traders seeking the latest updates and insights on ProKidney stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ProKidney's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ProKidney's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.72%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.74%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.28%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
ProKidney Corp.

Nasdaq:PROK

PROK Rankings

PROK Stock Data

215.42M
43.48M
23.14%
60.71%
22.69%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
WINSTON-SALEM

About PROK

prokidney (nasdaq: prok), a pioneer in the treatment of ckd through innovations in cellular therapy, was founded in 2015 after a decade of research. prokidney’s lead product candidate, react™ (renal autologous cell therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of ckd, but in some cases potentially drive meaningful improvement in kidney function. late-stage ckd, stage 3b - 4, is a key target for react™ therapy. react™ has received regenerative medicine advanced therapy (rmat) designation, as well as fda and ema guidance, supporting its ongoing phase 3 clinical program, which launched in january 2022. for more information, visit www.prokidney.com.